Flupentixol + Melitracen Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: Flupentixol 0.5 mg + Melitracen 10 mg
Reference Brands: Deanxit(EU)
Category:
Antipsychotropic Drugs
Flupentixol + Melitracen, available as Deanxit, is a trusted antidepressant-anxiolytic combination widely used in EU and international markets. With strengths of 0.5 mg + 10 mg, it is ideal for psychosomatic disorders. Pharma B2B buyers source this product from global GMP-certified suppliers for psychiatric medicine portfolios.
Flupentixol + Melitracen is available in Tablets
and strengths such as Flupentixol 0.5 mg + Melitracen 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Flupentixol + Melitracen is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Flupentixol + Melitracen can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Flupentixol + Melitracen is a well-established combination therapy for managing depression and anxiety, especially in psychosomatic and somatic conditions. Available as oral tablets (Flupentixol 0.5 mg + Melitracen 10 mg), this dual-action formulation provides both antidepressant and anxiolytic benefits. The most popular brand, Deanxit, is marketed in various EU and international markets. Although not FDA-approved for use in the US, this fixed-dose combination sees significant demand in Europe, Asia, and the Middle East. Global pharmaceutical importers and B2B buyers rely on GMP-compliant suppliers to source Flupentixol + Melitracen for mental health therapeutic segments.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing